Levetiracetam Does Not Cause Hyperkalemia
Levetiracetam is not associated with elevated potassium levels; in fact, the available evidence suggests it may cause hypokalemia (low potassium), not hyperkalemia. This is an important distinction that contradicts the premise of your question.
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for levetiracetam does not list hyperkalemia or elevated potassium as an adverse effect 111. The documented adverse events in clinical trials included somnolence, dizziness, asthenia, infection, and neuropsychiatric effects, but no mention of potassium elevation appears in the comprehensive safety data.
Emerging Evidence of Hypokalemia Risk
Contrary to causing elevated potassium, levetiracetam has been associated with hypokalemia (low potassium) in several case reports and observational studies:
A 2024 real-world evidence study found an incidence rate of hypokalemia of 303 cases per 10,000 patient-years in levetiracetam-exposed patients, with an adjusted hazard ratio of 1.99 compared to carbamazepine users 2
Multiple case reports document levetiracetam-induced hypokalemia, including cases of refractory hypokalemia requiring medication discontinuation 34
One case described potassium levels dropping to 2.0 mmol/L despite aggressive repletion, which only corrected after switching from levetiracetam to lacosamide 3
Clinical Implications
If you observe elevated potassium in a patient taking levetiracetam, you should look elsewhere for the cause. The comprehensive European Society of Cardiology guidelines on hyperkalemia management list numerous medications that cause elevated potassium 555, including:
- RAAS inhibitors (ACE inhibitors, ARBs, mineralocorticoid receptor antagonists)
- Potassium-sparing diuretics (spironolactone, amiloride, triamterene)
- Beta-blockers
- NSAIDs
- Trimethoprim-sulfamethoxazole
- Calcineurin inhibitors
- Heparin
Levetiracetam does not appear on this list.
What to Monitor
Rather than monitoring for hyperkalemia with levetiracetam, clinicians should be aware of the potential for hypokalemia and hypomagnesemia, particularly in patients receiving high doses or those with other risk factors for electrolyte disturbances 4. If refractory hypokalemia develops in a patient on levetiracetam, consider switching to an alternative antiepileptic medication 3.